Matt O'Brien
Stock Analyst at Piper Sandler
(2.38)
# 2,621
Out of 5,090 analysts
195
Total ratings
46.63%
Success rate
-2.38%
Average return
Main Sectors:
Stocks Rated by Matt O'Brien
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TELA TELA Bio | Reiterates: Neutral | $2 → $1.25 | $1.15 | +8.70% | 7 | Nov 14, 2025 | |
| SI Shoulder Innovations | Reiterates: Overweight | $18 | $15.20 | +18.42% | 2 | Nov 12, 2025 | |
| CNMD CONMED | Maintains: Overweight | $68 → $55 | $40.07 | +37.26% | 14 | Nov 6, 2025 | |
| PRCT PROCEPT BioRobotics | Reiterates: Overweight | $55 → $50 | $35.86 | +39.43% | 5 | Nov 5, 2025 | |
| DXCM DexCom | Maintains: Overweight | $100 → $75 | $65.49 | +14.52% | 13 | Oct 31, 2025 | |
| ATEC Alphatec Holdings | Reiterates: Overweight | $20 → $25 | $21.45 | +16.55% | 4 | Oct 31, 2025 | |
| TMDX TransMedics Group | Maintains: Overweight | $145 → $140 | $136.51 | +2.56% | 13 | Oct 30, 2025 | |
| BBNX Beta Bionics | Reiterates: Overweight | $26 → $32 | $29.38 | +8.92% | 2 | Oct 29, 2025 | |
| ITGR Integer Holdings | Maintains: Overweight | $155 → $82 | $69.84 | +17.41% | 3 | Oct 24, 2025 | |
| KIDS OrthoPediatrics | Maintains: Overweight | $30 → $22 | $18.42 | +19.44% | 3 | Oct 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $18 | $13.26 | +35.75% | 1 | Aug 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $30 → $14 | $20.92 | -33.08% | 9 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 → $80 | $91.10 | -12.18% | 12 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $12 | $9.05 | +32.60% | 9 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $180 → $165 | $108.51 | +52.06% | 10 | Apr 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $27 | $24.07 | +12.17% | 1 | Mar 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $5.5 → $3.5 | $8.05 | -56.52% | 7 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $255 → $140 | $120.50 | +16.18% | 5 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $285 → $310 | $304.49 | +1.81% | 8 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $250 → $330 | $300.66 | +9.76% | 13 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $50 | $39.86 | +25.44% | 3 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $40 → $16 | $25.38 | -36.96% | 7 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $95 → $115 | $97.52 | +17.92% | 3 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $9 → $12 | $3.50 | +242.86% | 7 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $380 → $420 | $364.02 | +15.38% | 12 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $85 → $90 | $101.36 | -11.21% | 9 | Aug 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $25 | $19.68 | +27.03% | 1 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $3.5 → $3 | $1.23 | +143.90% | 2 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $4 → $4.5 | $3.94 | +14.21% | 2 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $94.28 | - | 2 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $15 | $4.40 | +240.91% | 1 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $93 → $109 | $81.40 | +33.60% | 1 | Feb 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $18 | $0.89 | +1,942.70% | 2 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $100 → $80 | $18.54 | +331.50% | 1 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $12 | $5.57 | +115.44% | 1 | Jun 24, 2020 |
TELA Bio
Nov 14, 2025
Reiterates: Neutral
Price Target: $2 → $1.25
Current: $1.15
Upside: +8.70%
Shoulder Innovations
Nov 12, 2025
Reiterates: Overweight
Price Target: $18
Current: $15.20
Upside: +18.42%
CONMED
Nov 6, 2025
Maintains: Overweight
Price Target: $68 → $55
Current: $40.07
Upside: +37.26%
PROCEPT BioRobotics
Nov 5, 2025
Reiterates: Overweight
Price Target: $55 → $50
Current: $35.86
Upside: +39.43%
DexCom
Oct 31, 2025
Maintains: Overweight
Price Target: $100 → $75
Current: $65.49
Upside: +14.52%
Alphatec Holdings
Oct 31, 2025
Reiterates: Overweight
Price Target: $20 → $25
Current: $21.45
Upside: +16.55%
TransMedics Group
Oct 30, 2025
Maintains: Overweight
Price Target: $145 → $140
Current: $136.51
Upside: +2.56%
Beta Bionics
Oct 29, 2025
Reiterates: Overweight
Price Target: $26 → $32
Current: $29.38
Upside: +8.92%
Integer Holdings
Oct 24, 2025
Maintains: Overweight
Price Target: $155 → $82
Current: $69.84
Upside: +17.41%
OrthoPediatrics
Oct 10, 2025
Maintains: Overweight
Price Target: $30 → $22
Current: $18.42
Upside: +19.44%
Aug 18, 2025
Initiates: Overweight
Price Target: $18
Current: $13.26
Upside: +35.75%
Aug 7, 2025
Downgrades: Neutral
Price Target: $30 → $14
Current: $20.92
Upside: -33.08%
May 9, 2025
Maintains: Overweight
Price Target: $100 → $80
Current: $91.10
Upside: -12.18%
May 9, 2025
Maintains: Overweight
Price Target: $20 → $12
Current: $9.05
Upside: +32.60%
Apr 15, 2025
Maintains: Overweight
Price Target: $180 → $165
Current: $108.51
Upside: +52.06%
Mar 31, 2025
Initiates: Overweight
Price Target: $27
Current: $24.07
Upside: +12.17%
Mar 6, 2025
Maintains: Neutral
Price Target: $5.5 → $3.5
Current: $8.05
Upside: -56.52%
Feb 28, 2025
Downgrades: Neutral
Price Target: $255 → $140
Current: $120.50
Upside: +16.18%
Feb 21, 2025
Maintains: Overweight
Price Target: $285 → $310
Current: $304.49
Upside: +1.81%
Feb 19, 2025
Reiterates: Overweight
Price Target: $250 → $330
Current: $300.66
Upside: +9.76%
Feb 13, 2025
Maintains: Overweight
Price Target: $40 → $50
Current: $39.86
Upside: +25.44%
Feb 12, 2025
Maintains: Neutral
Price Target: $40 → $16
Current: $25.38
Upside: -36.96%
Feb 3, 2025
Maintains: Overweight
Price Target: $95 → $115
Current: $97.52
Upside: +17.92%
Nov 8, 2024
Reiterates: Neutral
Price Target: $9 → $12
Current: $3.50
Upside: +242.86%
Oct 30, 2024
Reiterates: Overweight
Price Target: $380 → $420
Current: $364.02
Upside: +15.38%
Aug 21, 2024
Maintains: Neutral
Price Target: $85 → $90
Current: $101.36
Upside: -11.21%
Mar 28, 2024
Initiates: Overweight
Price Target: $25
Current: $19.68
Upside: +27.03%
Nov 10, 2023
Maintains: Neutral
Price Target: $3.5 → $3
Current: $1.23
Upside: +143.90%
Aug 11, 2023
Maintains: Overweight
Price Target: $4 → $4.5
Current: $3.94
Upside: +14.21%
Mar 10, 2023
Upgrades: Overweight
Price Target: n/a
Current: $94.28
Upside: -
Feb 24, 2023
Initiates: Overweight
Price Target: $15
Current: $4.40
Upside: +240.91%
Feb 11, 2021
Maintains: Overweight
Price Target: $93 → $109
Current: $81.40
Upside: +33.60%
Jan 29, 2021
Downgrades: Neutral
Price Target: $25 → $18
Current: $0.89
Upside: +1,942.70%
Jan 29, 2021
Downgrades: Neutral
Price Target: $100 → $80
Current: $18.54
Upside: +331.50%
Jun 24, 2020
Initiates: Overweight
Price Target: $12
Current: $5.57
Upside: +115.44%